Pacira BioSciences, Inc. — Director's Dealing 2021

Apr 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-03-31

Reporting Person: WINSTON ROY (Chief Clinical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-31	Common Stock	M	13750	$34.375	Acquired	48535	Direct
2021-03-31	Common Stock	S	16363	$70.36	Disposed	32172	Direct
2021-03-31	Common Stock	S	4661	$71.09	Disposed	27511	Direct
2021-03-31	Common Stock	S	1200	$72.12	Disposed	26311	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-31	Stock Option (Right to Buy)	$34.375	M	13750	Disposed	2028-05-02	Common Stock (13750)	Direct

Footnotes

F1: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.80 to $70.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 through 4.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.80 to $71.79, inclusive.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.80 to $72.48, inclusive.

F5: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.